The Effect of Vitamin A Supplementation on FoxP3 and TGF-β Gene Expression in Avonex-Treated Multiple Sclerosis Patients

Journal of Molecular Neuroscience

Volumn 56, Issue 3, 2015, Pages 608-612

  Saboor Yaraghi, Ali Akbar ^a,e   Harirchian, Mohammad Hossein ^b   Mohammadzadeh Honarvar, Niyaz ^a   Bitarafan, Sama ^b   Abdolahi, Mina ^a   Siassi, Feridoun ^a   Salehi, Eisa ^c   Sahraian, Mohammad Ali ^d   Eshraghian, Mohammad Reza ^e   Roostaei, Tina ^b   Koohdani, Fariba ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

FoxP3; Gene expression; Multiple sclerosis; TGF ; Vitamin A

Indexed keywords

BETA1A INTERFERON; COMPLEMENTARY DNA; PLACEBO; RETINOL PALMITATE; RNA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; RETINOL; VITAMIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT DURATION; UPREGULATION; VITAMIN SUPPLEMENTATION; DIET SUPPLEMENTATION; GENETICS; METABOLISM; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIAL;

ADULT; DIETARY SUPPLEMENTS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON BETA-1A; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; VITAMIN A; VITAMINS;

EID: 84931567920     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-015-0549-y     Document Type: Article

References (42)

1. Alberts D, Ranger-Moore J et al (2004) Safety and efficacy of dose intensive oral vitamin A in subjects with sun-damaged skin. Clin Cancer Res 10(6):1875–1880
2. Boppana S, Huang H, Ito K, Dhib-Jalbut S (2011) Immunologic aspects of multiple sclerosis. Mt Sinai J Med 78(2):207–220
3. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E (2009) Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 132(Pt 12):3329–41
4. Buc M (2013) Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis. Mediators Inflamm 2013:963748
5. Cassani B, Villablanca EJ, De Calisto J, Wang S, Mora JR (2012) Vitamin A and immune regulation: role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance. Mol Aspects Med 33(1):63–76
6. Chang J, Thangamani S, Kim MH, Ulrich B, Morris SM, Kim CH (2013) Retinoic acid promotes the development of Arg1-expressing dendritic cells for the regulation of T-cell differentiation. Eur J Immunol 43(4):967–78
7. Den Hartog G, van Altena C, Savelkoul HF, van Neerven RJ (2013) The mucosal factors retinoic acid and TGF-beta1 induce phenotypically and functionally distinct dendritic cell types. Int Arch Allergy Immunol 162(3):225–36
8. Di Caro V, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N (2013) Retinoic acid-producing, ex vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B-lymphocytes. Clin ExpImmunol 174:302–17
9. Elias KM, Laurence A, Davidson TS et al (2008) Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111(3):1013–20
10. Elyaman W, Bradshaw EM, Uyttenhove C et al (2009) IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA 106:12885–90
11. Haas J, Korporal M, Schwarz A, Balint, Wildemann B (2011) The interleukin-7 receptor α chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis. Eur J Immunol 41:845–53
12. Hall JA, Grainger JR, Spencer SP, Belkaid Y (2011) The role of retinoic acid in tolerance and immunity. Immunity 35:13–22
13. Honarvar NM, Harrirchian MH, Koohdani F et al (2013) In vitro effect of human serum and fetal calf serum on CD4+ T cells proliferation in response to myelin oligodendrocyte glycoprotein (MOG) in correlation with RBP/TTR ratio in multiple sclerotic patients. J Mol Neurosci 50(3):571–6
14. Huan J, Culbertson N, Spencer L et al (2005) Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 81:45–52
15. Jadidi-Niaragh F, Mirshafiey A (2011) Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol 74(1):1–13
16. Langrish CL, Chen Y, Blumenschein WM et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201(2):233–40
17. Løken-Amsrud KI, Myhr KM, Bakke SJ, Beiske AG et al (2013) Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Mult Scler 19:451–7
18. Lovett-Racke AE, Yang Y, Racke MK (2011) Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta 1812(2):246–51
19. Lowther DE, Hafler DA (2012) Regulatory T cells in the central nervous system. Immunol Rev 248:156–169
20. Lu L, Zhou X, Wang J, Zheng SG, Horwitz DA (2010) Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-β and retinoic acid. PLoS One 5(12):e 15150
21. Mohammadzadeh Honarvar N, Harirchian MH, Koohdani F et al (2013) The effect of vitamin A supplementation on retinoic acid-related orphan receptor γt (RORγt) and interleukin-17 (IL-17) gene expression in Avonex-treated multiple sclerotic patients. J Mol Neurosci 51(3):749–53
22. Mottaghi A, Salehi E, Sezavar H et al (2012) The in vitro effect of oxidized LDL and PHA on proliferation and gene expression of regulatory T cells in patients with atherosclerosis. Iran J Allergy Asthma Immunol 11(3):217–23
23. Mottaghi A, Salehi E, Sezavar H et al (2013) The influence of vitamin A supplementation on Foxp3 and TGF gene expression in atherosclerosis patients. J Nutrigenet Nutrigenomics 5(6):314–26
24. Mucida D, Park Y, Kim G (2007) Reciprocal Th17 and regulatory T cell differentiation mediated by retinoic acid. Science 317(5835):256–60
25. Mucida D, Pino-Lagos K, Kim G et al (2009) Retinoic acid can directly promote TGF-beta-mediated Foxp3 (+) Treg cell conversion of naive T cells. Immunity 30(4):471–2
26. Parés X, Farrés J, Kedishvili N, Duester G (2008) Medium-chain and short-chain dehydrogenases/reductases in retinoid metabolism. Cell Mol Life Sci 65(24):3936–49
27. Pino-Lagos K, Benson MJ, Noelle RJ (2008) Retinoic acid in the immune system. Ann N YAcadSci 1143:170–87
28. Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500
29. Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P (2013) Vitamin A and systemic inflammation as protective factors in multiple sclerosis. Mult Scler 19:1046–51
30. Samarut E, Rochette-Egly C (2011) Nuclear retinoic acid receptors: conductors of the retinoic acid symphony during development. Mol Cell Endocrinol 348(2):348–60
31. Schambach F, Schupp M, Lazar MA, Reiner SL (2007) Activation of retinoic acid receptor-a favors regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur J Immunol 37(9):2396–9
32. Sedjo RL, Ranger-Moore J, Foote J et al (2004) Circulating endogenous retinoic acid concentrations among participants enrolled in a randomized placebo-controlled clinical trial of retinylpalmitate. Cancer Epidemiol Biomarkers Prev 13(11 Pt 1):1687–92
33. Steinman L (2014) Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 32:257–81
34. Takahashi H, Kanno T, Nakayamada S et al (2012) TGF-b and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. Nat Immunol 13:587–95
35. Veldhoen M, Stockinger B (2006) TGFbeta1, a Jack of all trades: the link with pro-inflammatory IL-17-producing T cells. Trends Immunol 27(8):358–61
36. Venken K, Hellings N, Hensen K et al (2006) Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4 + CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 83(8):1432–46
37. Weaver CT, Hatton RD (2009) Interplay between the Th17 and Treg cell lineages: a (co)evolutionary perspective. Nat Rev Immunol 9:883–9
38. Xiao S, Jin H, Korn T (2008) Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGFbeta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 181(4):2277–84
39. Yurchenko E, Shio MT, Huang TC et al (2012) Inflammation driven reprogramming of CD4 + Foxp3+ regulatory T cells into pathogenic Th1/Th17 effectors is abrogated by mTOR inhibition in vivo. PLoS One 7(4):355–72
40. Ziegler SF, Buckner JH (2009) FOXP3 and the regulation of Treg/Th17differentiation. Microbes Infect 11:594–8
41. Ziouzenkova O, Plutzky J (2008) Retinoid metabolism and nuclear receptor responses: new insights into coordinated regulation of the PPAR– RXR complex. FEBS Lett 582(1):32–8
42. Zúñiga LA, Jain R, Haines C, Cua DJ (2013) Th17 cell development: from the cradle to the grave. Immunol Rev 252:78–88